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the largest studies comparing the 2 procedures were published last
year. Hence, we performed an updated systematic review to compare
ASA and SM. Our primary aim was to compare the efﬁcacy of both
strategies in improving patient’s symptoms. Secondly, we wanted to
assess if there is any signiﬁcant difference in short and long term
mortality between the 2 approaches.
METHODS A comprehensive search strategy was designed and a thor-
ough computer based search was performed using OVID MEDLINE,
EMBASE and PubMed databases. No time limit to start date was applied
and the search was conducted up to 29 March 2015. We reviewed both
the identiﬁed manuscripts and references cited or citing indexed
studies. Of 1143 citations, 10 studies were included in the analysis.
RESULTS There were a total of 1824 patients with obstructive symp-
tomatic HCM of which 859 (44%) were treated with ASA and 1019 (56%)
with SM. Gender characteristics were available in 8 studies. Fifty-one
percent of patients in both of the groups were men (ASA¼349/677 and
SM¼367/721).The average follow-up in the ASA groupwas 2.9 2 years,
while SM patients were followed up for 4.5  4.4 years. Patients un-
dergoing SM were relatively younger (MD 6.3, 95% CI 3.06 to 9.55, p ¼
0.0001, I2 ¼ 73%) and had higher reduction in the LVOT gradient from
baseline ((MD -9.56, 95%CI -19.15 to 0.04, p¼0.05, I2¼ 95%). However,
there was similar resolution of class III and IV symptoms between the 2
groups (OR 1.21, 95% CI 0.29 to 5.14, p ¼ 0.56, I2 ¼ 0%) . There was no
difference in the sudden cardiac death (SCD) (OR 1.04 95% CI 0.44 –
2.48, p ¼ 0.93, I2 ¼ 0%), short-term (p ¼ 0.36), long-term all cause (OR
0.76 95%CI 0.47 – 1.24, p ¼ 0.27, I2 ¼ 28%) and long-term cardiac mor-
tality (OR 0.74 95% CI 0.26 – 2.14, p ¼ 0.58, I2 ¼ 63%). Patients under-
going ASA had higher incidence of post procedure pacemaker implant
(OR 3.09 95% CI 1.89 – 5.07, p < 0.00001, I2 ¼ 11%) and a repeat proce-
dure (OR 5.68 95% CI 2.59 – 12.47, p < 0.0001, I2 ¼ 0%).
CONCLUSIONS In conclusion, ASA and SM are equally effective to
resolve LVOTO related symptoms in patients diagnosed with HCM.
There is no difference in the early and late mortality between the 2
procedures. Neither there is any difference in the events of SCD. ASA
is less invasive but comes at the cost of higher requirement of pace-
maker implant because of conduction abnormalities post procedure.
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BACKGROUND Alcohol septal ablation (ASA) and surgical myectomy
are invasive treatment options available to patients with drug-re-
fractory, obstructive, hypertrophic cardiomyopathy (HCM). Expert
consensus guidelines recommend myectomy as the ﬁrst line option,
with ASA available for patients at high surgical risk or due to patient
preference. However, there is a paucity of data describing clinical
outcomes following a guideline-based strategy when assessing pa-
tients for invasive septal reduction therapy.
METHODS We sought to deﬁne long-term outcome in HCM patients
undergoing myectomy or ASA in a large HCM referral center, where
management recommendations have been based on 2003 ACC/ESC
and 2011 ACCF/AHA consensus guidelines. Clinical outcomes were
analyzed in 258 consecutive patients who underwent myectomy or
ASA between 2004 and 2012, over a mean follow-up of 4.0  2.2 years.
RESULTS Of the 258 patients, 207 (80%) were referred for myectomy
and 51 (20%) for ASA (40 because of perceived high-risk substrate and 11
due to personal preference). There were no differences at baseline be-
tween the two groups with respect to numerous co-morbidities (COPD,
CVA, diabetes, CKD, liver disease, and metastatic cancer), however,
when compared tomyectomypatients, ASApatientswere older (64 10
vs. 51  15 years; p <0.001), more commonly female (57% vs 41%;
p¼0.06), and had a higher risk score using the modiﬁed Charlson Score
index (3.4  1.4 vs. 2.3  1.4; p<0.001). Compared to ASA, patients who
underwent myectomy achieved a greater improvement in heart failure
symptoms compared to ASA (class I: 58% vs. 33%; p ¼0.003), while the
repeat procedure rate was more common after ASA (0.5% vs. 8%;
p ¼0.006). During follow-up there were 12 deaths, including 10 in pa-
tients who underwent myectomy and 2 following ASA. All-cause mor-
tality was 1.1%/year (0.9%/yr in ASA vs. 1.4%/yr in myectomy patients;p¼0.6) which did not differ when compared with age and gender-
matched US population (p¼0.8) (Figure).
CONCLUSIONS Guideline-based referral for septal reduction therapy
in drug-refractory HCM patients is associated with low mortality rates
for both ASA and myectomy, although there was greater improvement
in limiting heart failure symptoms in the younger, lower-risk myec-
tomy patients. These data substantiate a strategy of decision-making
for invasive septal reduction therapy based on the current expert
consensus guidelines.
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BACKGROUND Many studies have evaluated the safety and efﬁcacy
of alcohol septal ablation (ASA) in symptomatic patients with hyper-
trophic obstructive cardiomyopathy (HOCM), although there are still
no randomised trials, transcatheter ASA is a viable alternative for
patients with HOCM.
METHODS From2009 to 2015 89ASAperformed in 86patients (58males,
28 females)withHOCMatour center.Meanageof pts.was43 [6;76] years.
Temporary pacemaker lead was placed through a femoral or jugular
venous sheath in the right ventricular apex before ASA, also all pts. un-
dergone myocardial contrast echocardiography (MCE) before procedure.
Mean peak pressure gradient (PG) on LVOTwas 93,48,2 mm. Hg. Mitral
valve regurgitation (MR) more than moderate was in all pts. Mean
interventricular septum thickness was 2,5cm [1,6; 3,3].
RESULTS Mean PG on LVOT decreased from 93,48,2 mmHg to
35,34,6 mmHg. The grade of MR reduced from at least moderate to
mild or even trivial. In 3 cases was recorded the complete disap-
pearance of MR. The procedure – related mortality was 0%. In 2 cases
(2,3%) the procedure was aborted by the coronary angiography and
MCE data. Mean follow-up for 86pts (100%) was 684,1 months.
71(83%) pts had PG reduction (to 30 mmHg) – regarded as good result
of procedure. 11 (12,4%) pts had PG > 30mmHg, but signiﬁcant
improvement in symptoms. 1(1,1%) case of sudden death 6 mounts
after procedure. 3(3,5%) pts needed redo procedure due to residual
LVOTO. All redo pts had effective systolic PG decreasing after second
procedure. 6(6,7%) patients had complete AV block and required
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cedure in anamnesis, 3 pts had initial changes on ECG. In 1 case we
had alcohol leakage from septal branch to LAD – aspiration, absence of
MACE. Also we had 1 case of ventricular ﬁbrillation on the 10-th day
after procedure. Mean interventricular wall thickness decreased from
2,5  0,3cm to 1,9  0,1cm. MR decreased from at least moderate to
mild or complete disappearance. NYHA class reduced from 2,9 to 1,1.
CONCLUSIONS ASA is effective and safe method of HOCM treatment.
The reduction of the duration of the procedure, decreasing of the number
of the complications and general improvement of the results of interven-
tional HOCM treatment are possible with accumulation of the experience.
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BACKGROUND Septal myectomy is the gold standard for medically-
refractory patients with hypertrophic obstructive cardiomyopathy
(HCM). There is a subset of patients who have severe exertional
symptoms without a resting or provocable left ventricular outﬂow
tract (LVOT) gradient on noninvasive testing. These patients may
demonstrate obstruction on hemodynamic catheterization with
isoproterenol challenge but is has remained unclear how they respond
to septal reduction therapy. We aimed to assess the ability of
isoproterenol challenge to predict symptom resolution with myec-
tomy in a selected HCM population.
METHODS 18 symptomatic HCM patients (NYHA class III or IV) with
labile obstruction on isoproterenol challenge underwent surgical
myectomy between February 2003 and April 2009. Patients were
reassessed for symptom resolution after a median of 4 (IQR 3-7) years.
RESULTS Post-myectomy, 13 patients (72.2%) had complete symptom
resolution, while 5 (27.8%) had improved but persistent symptoms. Pa-
tients with complete symptom resolution had a greater increase in left
atrial pressure (LAP) and tau with isoproterenol [3 (IQR -2-8) mmHg vs. -5
(IQR -8.5–1) mmHg; p¼0.01] and [-0.7 (IQR -13-22) ms vs. -44 (IQR -48–0.2)
ms; p¼0.03] (Figure 1). The mean change in LVOT gradient with peak
isoproterenol was signiﬁcantly greater among patients with complete
symptom resolution compared to patients with improved but persistent
symptoms [(104 (IQR 66-123) mmHg vs. 55 (IQR 38-74) mmHg; p¼0.01).
All patients with increase in LAP with isoproterenol and LVOT gradient
>100 mmHg achieved complete symptom resolution.CONCLUSIONS Patients with residual symptoms post-myectomy had
less increase in LAP and tau with isoproterenol indicating a “ﬁxed”
component to diastolic ﬁlling, as opposed to patients with symptom
resolution whose response was indicative of elevation in ﬁlling pres-
sures secondary to dynamic obstruction.
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BACKGROUND Current practice guidelines suggest that ASA may be
the treatment of choice for elderly patients with medically refractory
symptomatic HOCM because of the risks associated with cardiac sur-
gery in this patient population. We sought to determine the outcomes
and complications in elderly patients who undergo ASA.
METHODS 220 alcohol septal ablations were performed on 198 pa-
tients age 65 years or older (age 73 5y, 68% F) over a 15 year period.
Subgroup analyses were performed for patients 75 years of age
(n¼73, 80% F) and for patients age 65-74 (n¼125, 61% F).
RESULTS Of 220 ASA procedures performed, the primary endpoint of
in-hospital death occurred in four patients (1.8%). Among patients 
75 years of age (79 procedures) three patients died (4%) compared to
one death (0.7%) among patients age 65-74 years of age (141 ASA
procedures). 26 (11.8%) were repeat ablations. Complete heart block
(CHB) requiring permanent pacemaker occurred in 21 patients (9.5%).
For patients age  75 years the rate CHB requiring pacemaker im-
plantation was 11.3%. Bleeding or access site complications were re-
ported in eight patients (4.1%) among the entire cohort. Bleeding or
access site complications occurred in ﬁve patients (3.5%) who were 
75 years of age at the time of procedure.
CONCLUSIONS This study shows the safety of ASA in elderly patients.
Compared to the entire cohort of patients all ages undergoing ASA, the
elderly did not have a statistically signiﬁcant difference in complete
heart block requiring pacemaker implantation, bleeding/access site
complications, or procedural mortality. Although mortality rate of the
elderly cohort was not increased over historic controls, patients >75
years of age had statistically signiﬁcant higher mortality than patients
65-74 years of age.65-75y >75y Total P-ValueNumber of patients
(procedures)125 (141) 73 (79) 198 (220) -Deaths: number (%) 1 (0.7%) 3(4%) 4(1.8%) 0.0002CHB: number(%) 12 (5.4%) 9 (11.3%) 21 (9.5%) 0.39Bleeding/access
complication4 (5.0%) 5 (3.5%) 9(4.1%) 0.21CATEGORIES STRUCTURAL: Alcohol Septal Ablation/HOCM
KEYWORDS Ablation, alcohol septal, Hypertrophic cardiomyopathy
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BACKGROUND Alcohol septal ablation (ASA) is an established treat-
ment for symptomatic hypertrophic obstructive cardiomyopathy
(HOCM). The impact of race and gender on the results of ASA in pa-
tients with HOCM has not been reported in the literature.
METHODS Six hundred and forty-ﬁve patients with symptomatic HOCM
despite optimal medical therapy underwent ASA at a single center over a
ﬁfteen-year timeperiod (1999 to 2014). All patientswere grouped according
